➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
McKesson
Boehringer Ingelheim
Baxter
McKinsey

Last Updated: April 20, 2021

DrugPatentWatch Database Preview

EPOGEN/PROCRIT Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Tradename: EPOGEN/PROCRIT
Patents:99
Applicants:1
BLAs:1
Suppliers: see list2
Recent Clinical Trials: See clinical trials for EPOGEN/PROCRIT
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for EPOGEN/PROCRIT
Recent Clinical Trials for EPOGEN/PROCRIT

Identify potential brand extensions & biosimilar entrants

SponsorPhase
SandozPhase 3

See all EPOGEN/PROCRIT clinical trials

Recent Litigation for EPOGEN/PROCRIT

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Ameranth, Inc. v. Starbucks Corporation2013-05-06

See all EPOGEN/PROCRIT litigation

Pharmacology for EPOGEN/PROCRIT
Ingredient-typeErythropoietin
Physiological EffectIncreased Erythroid Cell Production

Company Disclosures: US Patents for EPOGEN/PROCRIT

These patents were extracted from company disclosures
Glossary
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Start Trial Kirin-Amgen, Inc. (Thousand Oaks, CA) 2012-08-15 RX company
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Start Trial Kirin-Amgen, Inc. (Thousand Oaks, CA) 2013-08-20 RX company
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Start Trial Kirin-Amgen, Inc. (Thousand Oaks, CA) 2003-12-13 RX company
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Start Trial Amgen Inc. (Thousand Oaks, CA) 2015-05-26 RX company
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Start Trial Kirin-Amgen, Inc. (Thousand Oaks, CA) 2016-09-21 RX company
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; MULTIDOSE 103234 002 1989-06-01   Start Trial Kirin-Amgen, Inc. (Thousand Oaks, CA) 2012-08-15 RX company
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; MULTIDOSE 103234 002 1989-06-01   Start Trial Kirin-Amgen, Inc. (Thousand Oaks, CA) 2013-08-20 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or Start Trial

Patent Text Search: US Patents for EPOGEN/PROCRIT

These patents were identified by searching patent claims
Glossary
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Start Trial SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) 2033-03-11 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Start Trial AMGEN INC. (Thousand Oaks, CA) 2039-02-26 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Start Trial 2036-04-01 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Start Trial MIDWESTERN UNIVERSITY (Downers Grove, IL) 2027-08-21 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Start Trial YALE UNIVERSITY (New Haven, CT) 2039-02-26 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Start Trial GENOSCIENCE PHARMA (Marseilles, FR) 2039-02-26 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Start Trial ChemoCentryx, Inc. (Mountain View, CA) 2036-06-13 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Mallinckrodt
Boehringer Ingelheim
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2021 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2021 - 2022
 NCE-1 Patent Challenge Dates 2021 - 2022
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2021, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group